Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sandner

Showing results (21-30 of 109) with videos related to

Pageof 11
Sort By:
Nitric Oxide : Biology and Chemistry|May 9, 2018
Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseasesPeter Sandner, Eva-Maria Becker-Pelster, Johannes Peter Stasch
Handbook of Experimental Pharmacology|December 21, 2016
The Three-Decade Long Journey in Heart Failure Drug DevelopmentKelly S Lewis, Javed Butler, Johann Bauersachs, et al.
European Journal of Pharmacology|March 27, 2025
Discovery of the first isoform-specific sGC activator: Selective activation of GC-1 by runcaciguatSvenja Stomberg, Anne Rühle, Theresa Wittrien, et al.
Pflugers Archiv : European Journal of Physiology|July 12, 2002
Cyclic AMP stimulates renin gene transcription in juxtaglomerular cellsJürgen Klar, Peter Sandner, Markus W H Müller, et al.
ESC Heart Failure|April 27, 2026
Use of sGC stimulators in heart failure therapy - a mode of action perspectiveFrank Ruschitzka, Robert Lukowski, Stefano Corda, et al.
FEBS Letters|September 17, 2011
Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciatedDaniel Reinecke, Heike Burhenne, Peter Sandner, et al.
European Journal of Pharmacology|May 25, 2020
Tyrosine 135 of the β<sub>1</sub> subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugsAnne Rühle, Christin Elgert, Michael G Hahn, et al.
The Journal of Sexual Medicine|February 21, 2013
Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failureMaarten Albersen, Loes Linsen, Hanna Tinel, et al.
Plos One|October 29, 2015
Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral CalculosisPeter Sandner, Hanna Tinel, Giannapia Affaitati, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 20, 2023
The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting reportAndreas Friebe, Jan R Kraehling, Michael Russwurm, et al.
Pageof 11

Showing results (21-30 of 109) with videos related to

Sort By:
Pageof 11
Nitric Oxide : Biology and Chemistry|May 9, 2018
Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseasesPeter Sandner, Eva-Maria Becker-Pelster, Johannes Peter Stasch
Handbook of Experimental Pharmacology|December 21, 2016
The Three-Decade Long Journey in Heart Failure Drug DevelopmentKelly S Lewis, Javed Butler, Johann Bauersachs, et al.
European Journal of Pharmacology|March 27, 2025
Discovery of the first isoform-specific sGC activator: Selective activation of GC-1 by runcaciguatSvenja Stomberg, Anne Rühle, Theresa Wittrien, et al.
Pflugers Archiv : European Journal of Physiology|July 12, 2002
Cyclic AMP stimulates renin gene transcription in juxtaglomerular cellsJürgen Klar, Peter Sandner, Markus W H Müller, et al.
ESC Heart Failure|April 27, 2026
Use of sGC stimulators in heart failure therapy - a mode of action perspectiveFrank Ruschitzka, Robert Lukowski, Stefano Corda, et al.
FEBS Letters|September 17, 2011
Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciatedDaniel Reinecke, Heike Burhenne, Peter Sandner, et al.
European Journal of Pharmacology|May 25, 2020
Tyrosine 135 of the β<sub>1</sub> subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugsAnne Rühle, Christin Elgert, Michael G Hahn, et al.
The Journal of Sexual Medicine|February 21, 2013
Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failureMaarten Albersen, Loes Linsen, Hanna Tinel, et al.
Plos One|October 29, 2015
Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral CalculosisPeter Sandner, Hanna Tinel, Giannapia Affaitati, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 20, 2023
The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting reportAndreas Friebe, Jan R Kraehling, Michael Russwurm, et al.
Pageof 11